Skip To Main Content

FAP-CD40

(RG6189)

Solid Tumor

Phase I

A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

NCT04857138